Marie Thibault
Stock Analyst at BTIG
(3.92)
# 617
Out of 4,901 analysts
75
Total ratings
56.76%
Success rate
8.93%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $30.26 | +71.84% | 7 | Apr 30, 2025 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $3.16 | +279.75% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $9.93 | +161.83% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $284.82 | -5.20% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $158.91 | +6.98% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $42.46 | +53.09% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $103.72 | -10.34% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $73.11 | +53.20% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $85.25 | +40.76% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $3.24 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.52 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $11.46 | +74.60% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $136.72 | +2.40% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.87 | -22.48% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $120.70 | +3.56% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.38 | +409.09% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.80 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.57 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $210.08 | -97.14% | 1 | Apr 9, 2020 |
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $30.26
Upside: +71.84%
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $3.16
Upside: +279.75%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $9.93
Upside: +161.83%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $284.82
Upside: -5.20%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $158.91
Upside: +6.98%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $42.46
Upside: +53.09%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $103.72
Upside: -10.34%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $73.11
Upside: +53.20%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $85.25
Upside: +40.76%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.24
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.52
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $11.46
Upside: +74.60%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $136.72
Upside: +2.40%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $3.87
Upside: -22.48%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $120.70
Upside: +3.56%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.38
Upside: +409.09%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.80
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.57
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $210.08
Upside: -97.14%